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Abstract
Purpose The purpose of this study was to establish the
influence of time interval between preoperative hyperfrac-
tionated radiotherapy (5×5 Gy) and surgery on long-term
overall survival (5 years) and recurrence rate in patients with
locally advanced rectal cancer operated on according to total
mesorectal excision technique.
Methods The treatment group comprised 154 patients with
locally advanced rectal cancer who were operated on be-
tween 1999 and 2006 in the 1st Department of General
Surgery, Jagiellonian University, Cracow, Poland. The data
on survival has been systematically collected until 31st of
December 2010. In addition, the following aspects were
analyzed: the significance of time interval between the end
of radiotherapy and surgical treatment and its influence on
downsizing, downstaging, rate of curative resections, and
sphincter-sparing procedures. Patients were qualified to pre-
operative radiotherapy 5×5 Gy and then randomly assigned
to subgroups with different time intervals between radio-
therapy and surgery: one subgroup consisted of 77 patients
operated on 7–10 days after the end of irradiation, and the
second subgroup consisted of 77 patients operated on after
4–5 weeks. Both groups were homogenous in sex, age,
cancer stage and localization, distal and circumferential
resection margins, and number of resected lymph nodes.
Results The 5-year survival rate in patients operated on 7–
10 days after irradiation was 63%, whereas in those operated
on after 4–5 weeks, it was 73%—the difference was not
statistically significant (log rank, p00.24). A statistically sig-
nificant increase in 5-year survival rate was observed only in
patients with downstaging after radiotherapy—90% in com-
parison with 60% in patients without response to neoadjuvant
treatment (log rank, p00.004). Recurrence was diagnosed in
13.2% of patients. A lower rate of systemic recurrence was
observed in patients operated on 4–5 weeks after the end of
irradiation (2.8% vs. 12.3% in the subgroup with a shorter
interval, p00.035). No differences in local recurrence rates
were observed in both subgroups of irradiated patients (p0
0.119). The longer time interval between radiotherapy and
surgery resulted in higher downstaging rate (44.2% vs. 13%
in patients with a shorter interval, p00.0001) although it did
notincreasetherateofsphincter-savingprocedures(p00.627)
and curative resections (p00.132).
Conclusions
1. Improved 5-year survival rate is observed only in
patients with downstaging after preoperative irradiation
dose of 25 Gy.
2. Longer time interval after preoperative radiotherapy
25 Gy does not improve the rate of sphincter-saving
procedures and curative resections (R0) despite higher
downstaging rate observed in this regimen.
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Colorectal cancer is a frequent neoplasm in both sexes.
Approximately 40% of all colorectal cancers are diagnosed
in the rectum. Surgery still remains the cornerstone of rectal
cancer treatment. Over recent decades, surgical therapy of
rectal cancer has witnessed a variety of developments until
present surgical quality standards could be achieved. Preop-
erative irradiation is reported to have less morbidity and be
more effective than postoperative regimens [1]. Two most
common regimens of preoperative radiotherapy exist. The
European model includes hyperfractionated treatment ap-
plied during 5 days (a total dose of 25 Gy) and operative
treatment during a week after the completion of the scheme.
The short delay is recognized to minimize postoperative
complications. The American model comprises chemoradio-
therapy (45–50 Gy +5-fluorouracil) and operative treatment
after 4–8 weeks. The literature is inconclusive regarding the
real value of preoperative irradiation and optimal time in-
terval before surgery has not been unequivocally established
so far. Currently, there are no enough randomized trials that
have reported whether there is a significant difference in
overall survival, recurrence rates, tumor downstaging, or
rate of sphincter-preserving procedures between these two
neoadjuvant therapy schedules. Surprisingly, data for the
association between time interval after preoperative radio-
therapy and long-term outcomes are scarce as well. The
influence of radiotherapy on survival was reported for the
first time in 1997 by Swedish scientists (Swedish Rectal
Cancer Trial), but potential flaws in this report (total meso-
rectal excision [TME] was not uniformly controlled) pre-
clude a reliable evaluation of data [2]. Other authors
diminish the role of radiotherapy particularly after introduc-
ing the TME technique, which enables better local clearance
and thus results in a lower rate of locoregional recurrences
[3]. The purpose of this randomized study was to ascertain
the relationship between time interval after radiotherapy and
long-term recurrence rate and overall survival of patients
undergoing resection for locally advanced rectal cancer after
neoadjuvant radiotherapy at a dose of 25 Gy.
Materials and methods
Patient selection
All patients with locally advanced rectal cancer after neo-
adjuvant radiotherapy 25 Gy operated on between 1999 and
2006 at the I
st Department of General Surgery in Krakow
were included in the study. The treatment group consisted of
154 patients who were qualified topreoperative radiotherapy
5×5 Gy and then randomly assigned to subgroups with dif-
ferent time intervals between radiotherapy and surgery: one
subgroup consisted of 77 patients operated on 7–10 days after
theendofirradiation,andthesecondsubgroupconsistedof77
patients operated on after 4–5 weeks. Computer-generated
randomization tables were used.
All relevant data including demographics, clinical and
histological staging, and details of diagnostic and surgical
procedures were collected prospectively using a standard
electronic database.
This study was approved by the Bioethics Committee of
the Jagiellonian University and has been performed in accor-
dance with the ethical standards laid down in the Declaration
of Helsinki. All patients gave their informed consent prior to
their inclusion in the study.
Treatment and follow-up
Preoperative irradiation was conducted at the Teleradiother-
apyDepartment,OncologicalCentre,Cracow,Poland.Itcom-
prised five doses of 5 Gy given for 5 consecutive days. Three-
portal technique, three-dimensional planning, and an energy
of 6 or 18 MV were used. The accelerators Clinac 600 and
Clinac 2300 were produced by Varian Medical Systems. The
dose was calculated according to ICRU 50 and ICRU 62
guidelines. Inconsistency of the dose distribution in the irra-
diated area varied from −5% to 5%. The surgical treatment
included TME with D3-lymphadenectomy, which followed
the recommendations of the Japanese Society for Cancer of
the Colon and Rectum. Anterior resection was performed if a
2-cm margin below tumor was possible to achieve. In other
cases, abdominoperineal resection was performed. Only few
patients underwent Hartmann procedure or local excision
(TEM). Follow-up data were collected based on clinical ex-
amination every 3 to 6 months after discharge, and dates of
death were verified using data obtained from the census
registry office. Survival rates were calculated based on the
overallsurvivalprinciple;thatis,deathsduetoanycausewere
accepted as complete observations, while lost to follow-up
was considered as a censored observation. Recurrence rates
were calculated only for patients who underwent potentially
curative resections (R0).
Statistical methods
Mann–Whitney U and χ
2 tests were used where appropriate
to compare the distribution of individual variables between
groups. Survival data were analyzed according to the
Kaplan–Meier method and included postoperative mortality;
the log-rank test was used to detect differences between
groups. p<0.050 was considered statistically significant. Sta-
tistical analyses were performed using the Statistica version
9.0 (Stat Soft Inc.) software package. The local and systemic
recurrencerateforpreoperativeradiotherapyandearlysurgery
was estimated at approximately 14% at 5 years, whereas the
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estimated as 2%. Sample Power release 2.0 (SPSS Inc.) was
used to calculate the population required to achieve a test
power of 80%. Sample size needed for each arm was estab-
lished as 80 patients (two-sided test, α00.05). The actual
recruitment in the study was slightly lower (77 patients in
both arms), so the actual power is lower than 80%. The study
was registered at ClinicalTrials.gov, identifier NCT01444495.
Results
Demographic data
Between 1999 and 2006, 154 patients were operated on after
neoadjuvant radiotherapy 5×5 Gy. Table 1 shows the clin-
icopathological features of the analyzed population. Both
analyzed groups were homogenous for age, sex, clinical
staging, tumor localization, and resection margins (Table 1).
Surgery
No significant differences between the analyzed groups
were observed for the type of resection, number of resected
lymph nodes, numbers of patients with at least 12 lymph
nodes retrieved, rates of potentially curative resections, and
rates of sphincter-saving procedures. The procedure of
choice was TME. All operations were performed by the
same team of surgeons trained in TME technique. D3-
lymphadenectomy was conducted as a standard procedure;
that is, mesorectal, inferior mesenteric and periaortic lymph
nodes to the level of pancreas were resected.
Recurrences
The recurrence rates altogether did not differ between the
analyzed groups. If specific types of recurrences were eval-
uated separately, more systemic recurrences were observed
in patients operated on after a short time interval between
the end of irradiation and surgery (12.3% vs. 2.8%, respec-
tively; p00.035). Rates of local recurrences did not differ
either (p00.119). The exact numbers and percentages of
recurrences are summarized in Table 2.
Long-term survival
Until the final follow-up (on December 31, 2010), 57 of 154
patients had died, and the median follow-up period for those
who survived was 86 months. The overall survival in patients
operated on after different time intervals between radiotherapy
andsurgery was similar(Fig. 1).Elongationof timeinterval did
not improve the survival rate. Survival benefit was observed
only in patients who responded to preoperative treatment, that
is, when downstaging was confirmed (Fig. 2). In this subgroup,
5-year overall survival was significantly higher than in the
patients who did not respond to radiotherapy (90% vs. 60%,
respectively; p00.004).
Downstaging
Staging of rectal cancer was performed according to the Union
for International Cancer Control/American Joint Committee of
Cancer (UICC/AJCC) 2002. Clinical stage of the neoplasm was
assessed in preoperative examinations performed before radio-
therapy: endorectal ultrasound, abdominal ultrasound, and chest
x-ray. Pathological TNM (ypTNM) was determined by a histol-
ogist after examination of the specimen. Downstaging was
recorded when pathological stage was lower than clinical stage
before neoadjuvant treatment. A change only in T feature with-
out change in cancer stage was not regarded as downstaging in
this study. Complete pathological response was defined as the
absence of a residual tumor at the time of histological examina-
tion of the resected specimen. Higher rates of patients respond-
ing to radiotherapy were observed after a longer delay between
irradiation and surgery (p00.0001). Complete responses were
observed only after a longer time interval in 10.4% of patients.
Discussion
The influence of preoperative radiotherapy on survival
Hyperfractionated radiotherapy and chemoradiotherapy
have been the principal neoadjuvant regimens assessed in
randomized trials on combined treatment of rectal cancer.
Short-course preoperative irradiation (a total dose of 25 Gy
divided into five fractions) was reported to have a survival
benefit in a Swedish Rectal Cancer Trial [2]. In that study,
patients were assigned to 1-week hyperfractionated radio-
therapy followed by surgery within 7 days versus surgery
alone. The 5-year overall survival rate was 58% in the
combined treatment group compared with 48% in the
surgery-alone group (p00.004). One flaw of the study is
that it was conducted prior to the introduction of TME as the
standard procedure. Furthermore, the study did not comprise
only patients with locally advanced neoplasm, as both arms
included subjects with Dukes A disease.
In another randomized study by Bujko et al. [4] (Polish
Trial), patients given chemoradiation compared with those
who underwent radiation alone (5×5 Gy) had no significant
difference in 4-year survival (66% vs. 67%, respectively).
The Dutch Rectal Cancer Study Group conducted a random-
ized trial to determine whether neoadjuvant radiation offers
any benefit to patients who uniformly undergo TME. Unlike
previously mentioned Swedish Trial, this study has not
shown a difference in overall survival [5]. Different lengths
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Swedish Trial, might be a substantial factor contributing to
this inconsistency. The latest update of the Dutch Trial
published in 2007 revealed no significant difference in
a 5-year overall survival either [6].
Our study is one of the first randomized trials where
long-term treatment results are summarized for the patients
operated on after a longer time interval following the pre-
operative hyperfractionated radiotherapy 25 Gy. Delay
of surgery (4–5 weeks after radiation) did not improve
Table 1 Patient characteristics in analyzed groups
Preoperative radiotherapy 25 Gy + surgery, n0154 p
Time interval 7–10 days, n07 Time interval 4–5 weeks, n077
Age (years), median (range) 61 (30–92) 62 (26–83) 0.87
a
Women 28 (36.4%) 38 (49.4%) 0.10
b
Men 49 (63.6%) 39 (50.6%)
Clinical staging of rectal cancer according to UICC (AJCC 2002)
I 9 (11.7%) 14 (18.2%) 0.686
b
II 45 (58.4%) 44 (57.1%)
III 23 (29.9%) 19 (24.7%)
Tumor localization (distance from anal verge)
<6 cm 28 (36.4%) 37 (48.1%) 0.14
b
7–12 cm 49 (63.6%) 40 (51.9%)
Mean resection margins (cm)
Proximal 15.83±7.27 14.67±6.30 0.303
a
Distal 4.30±1.89 4.20±2.36 0.778
a
Circumferential (radial) 1.11±1.1 1.27±1.13 0.618
a
Resected lymph nodes
Median (range) 16 (1–79) 15 (0–57) 0.204
a
Patients with ≥12 lymph nodes resected 56 (73%) 51 (66%) 0.382
b
Adjuvant chemotherapy
No. of patients (%) 53 (68.8) 51 (66.2) 0.731
b
Types of resection
Anterior resection 40 (51.9%) 40 (51.9%) 0.391
b
Abdominoperineal amputation 31 (20.1%) 25 (16.2%)
Hartmann procedure 5 (6.5%) 8 (10.4%)
TEM 0 4 (5.2%)
Other (hemicolectomy + anterior resection) 1 (1.3%) 0
Type of resection according to Hermanek
R0 65 (84.4%) 71 (92.2%) 0.239
b
R1 7 (9.1%) 2 (2.6%)
R2 5 (6.5%) 4 (5.2%)
Sphincter-saving operations
No. (%) 41 (53.2) 44 (57.1) 0.627
b
Response to radiotherapy
Downstaging 10 (13%) 34 (44.2%) 0.0001
b
Complete response 0 8 (10.4%) 0.003
b
Histological staging after radiotherapy (ypTNM, AJCC 2002)
0 1 (1.3%) 11 (14.2%) 0.003
b
I 20 (26%) 25 (32.5%)
II 18 (23.4%) 23 (29.9%)
III 34 (44.1%) 15 (19.5%)
IV 4 (5.2%) 3 (3.9%)
aMann–Whitney U test
bχ
2 Test
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mainly from the high quality surgery (TME was uniformly
controlled, and more than 70% of patients had at least 12
lymph nodes retrieved), and despite a higher downstaging
rate, no improvement in survival was achieved.
There are few ongoing trials that address the issue of optimal
time interval before surgery. The Stockholm III Trial is examin-
ing the different preoperative radiotherapy regimens and delay
to surgery—it is comparing 5×5-Gy radiotherapy and immedi-
ate surgery versus 5 × 5-Gy and delayed surgery versus 50-Gy
radiotherapy and delayed surgery [7]. The study purpose is to
determine whether the timing of surgery after radiation influen-
ces morbidity, mortality, and tumor downstaging. Unfortunately,
the results of this trial have not been published so far.
In our study, a significant survival benefit was observed in
patients who responded to radiotherapy; that is, when down-
staging was confirmed (5-year overall survival of 90% in com-
parison with 60% in the patients without response to
neoadjuvant treatment; log rank p00.004). Clinical data sup-
porting the importance of the downstaging and pathologic re-
sponse to preoperative radiotherapy are still abundant. Stipa et
al. [8], in a study conducted at Memorial Sloan-Kettering Can-
cer Centre, compared patients with locally advanced rectal
cancer who achieved a pathologic complete response with those
without difference between the clinical stage (determined in
endorectal ultrasound) and the pathologic stage. Results showed
a 5-year recurrence-free survival rate of 96% for patients achiev-
ing a complete response in comparison with 54% in the no-
downstaging group (p<0.00001). This result is similar to the
one observed in our research.
Although in our study, improvement of 5-year survival was
observed in the patients with successful downstaging and tumor
shrinkage was higher in patients allocated to delayed surgery,
the survival of the whole collective was not significantly im-
proved. This phenomenon might result from the fact that in
some patients who did not respond to radiotherapy, delay in
operative treatment led to tumor progression. Indeed, upstaging
was observed in 8 patients (10.4%) assigned to a long-interval
arm, and these individuals were obviously included in the
survival analysis. Even if progression was not apparently
noticed in nonresponders, they were probably more liable to
localorsystemic recurrence,which resulted inpoorer prognosis.
Influence of preoperative radiotherapy on recurrences
The risk of locoregional relapse of rectal cancer is affected by
involvement of the circumferential (radial) resection margin and
lymphnodestatus.Theconventionaltreatmentinmostcountries
for clinical stage T3 or node-positive rectal cancer is preopera-
tive treatment, since a significantly lower local recurrence rate
and morbidity were reported after preoperative than postopera-
tivechemoradiationintheGermanChirurgischeArbeitsgemein-
schaft für Onkologie/Arbeitsgemeinschaft Radiologische
Onkologie/Arbeitsgemeinschaft Internistische Onkologie
(CAO/ARO/AIO-94) trial [1].
In Swedish Rectal Cancer Trial, the local recurrence rate at a
5-year follow-up was 11% in the group receiving radiotherapy
prior to surgery and 27% in the group treated with surgery alone
(p<0.001) [2]. Bujko et al. [4] reported no significant difference
in local relapse for the patients who underwent different preop-
erative treatment schemes: chemoradiation or radiotherapy
Fig. 1 Overall survival in patients operated on after 7–10 days and 4–
5 weeks after preoperative radiotherapy 25 Gy (5-year survival rate,
63% vs. 73%; log rank, p00.24)
Fig. 2 Overall survival in patients with and without downstaging after
preoperative radiotherapy 25 Gy (5-year survival rate, 90% vs. 60%;
log rank, p00.004)
Table 2 Pattern of recurrences in analyzed groups
Time interval
7–10 days, n077
Time interval
4–5 weeks, n077
p
Local 1 (1.5%) 5 (7%) 0.119
Systemic 8 (12.3%) 2 (2.8%) 0.035
Local + systemic 0 2 (2.8%) 0.271
Total 9 (13.8%) 9 (12.7%) 0.520
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results of the Swedish group, as they reported local recurrence
rate of 2.4% at the 2-year follow-up in the radiotherapy and
surgery groups and 8.2% rate in the surgery-alone group (p<
0.001) [5]. The update of the trial published in 2007 revealed a
reduction in local failure from 21% to 11% for stage III patients
but no significant reduction for stage II patients [6]. In some
respect,thepromisingresultsofTMEchallengedtheadvantages
of preoperative irradiation. A Dutch TME Trial, however,
proved that neoadjuvant radiation reduced the local recurrence
rate also after TME [5, 6]. Furthermore, the Medical Research
Council CR07 trial (MRC CR07) showed that postoperative
chemoradiation for patients with positive circumferentialmargin
does not compensate for the beneficial effect of the routine use
of the short-course irradiation for all rectal cancer patients. In
this trial, 1,350 patients were randomized to TME preceded by
25 Gy in 1 week versus TME followed by chemoradiation if the
circumferential margin was positive. The rate of local recurrence
at 5 years was significantly better in the preoperative irradiation
group(5%)comparedwiththepostoperativeradiotherapygroup
(17%) (p<0.001). In multivariate analysis, the status of radial
margin was the strongest predictive factor for local relapse of
rectal cancer [9].
The hyperfractionated radiotherapy 5×5 Gy sterilizes the
surgical margins of mesorectum and prevents the growth of
residual foci of neoplastic cells. The oncological steriliza-
tion results in a lower rate of locoregional failure and may
potentially decrease distant spread of tumor cells. This
mechanism may explain the lower rate of distant metastases
detected in our research in patients operated on 4–5 weeks
after the end of radiotherapy. However, no difference in
local relapse was observed in groups with different time
intervals before surgery. In previously published studies,
the short scheme of radiotherapy did not downstage the
tumor when the time interval before operation was short
[10, 11]. On the contrary, in our study, 13% downstaging
rate was observed in the short-interval group. This discrep-
ancy may result from different timing of surgery: in our
research, patients were operated on 7–10 days after the
end of radiotherapy, whereas in other studies, the operation
was scheduled usually earlier (before 7th day).
Despite discrepancies in overall survival, the majority of
studies consistently showed that preoperative radiation ther-
apy provides a significant reduction in local recurrence for
locally advanced rectal cancers.
An ongoing trial by Garcia-Aguilar et al. is investigating
whether locally advanced rectal cancer response rates are
influenced by the delay of surgery after neoadjuvant chemo-
radiotherapy. Preoperative treatment consists of standard 5-
fluorouracil or the combination chemotherapy and radiother-
apy 45 Gy given over a 6-week period. Surgical treatment is
scheduled 6, 10, 14, or 19 weeks after neoadjuvant treatment
[7]. This trial will enable to determine the optimal time
interval to surgery in respect to achieving the best long-term
treatment results.
Sphincter preservation
Avoiding permanent stoma remains a crucial factor of quality
of life. During our trial, the required distal margin of rectal
cancer was at least 2cm toperform the operationwith sphincter
preservation. Although a significantly higher rate of tumor
shrinkage was achieved in the group with delayed surgery, it
had no effect on lowering the rate of permanent stoma in these
patients. This observation may be connected with applying a
rule of 2-cm distal margin as well as surgeons' skills, patients'
desire,andtumorlocalization.Inaddition,insomecases,tumor
shrinkage was not sufficient to translate into a significant
difference in the surgical approach. The issue of sphincter
preservation was addressed by at least 17 randomized trials
methodically reviewed by Gerard et al. [12]. They concluded
that in none of the large trials, neoadjuvant treatment was able
torevealanysignificantbenefitintermsof sphinctersaving.Few
randomized studies reported advantages of a particular preoper-
ativetherapy,buttheirresultscannotbewidelyimplementedinto
clinical practice due to the substantial flaws (low number of
patients included, only nonresectable or recurrent tumors) [13,
14]. On the other hand, the reappraisal of the rule of the 2 cm for
distal margin has increased the possibility of sphincter-saving
surgery, which should be evaluated in further studies.
Conclusions
An improved 5-year overall survival rate is observed only in
patients with downstaging after a preoperative radiotherapy
dose of 25 Gy. A longer time interval between radiotherapy
and surgery increases the downstaging rate in patients with
locally advanced rectal cancer. Preoperative radiotherapy
25 Gy does not improve the rate of sphincter-saving procedures
and potentially curative resections (R0). Appropriately defin-
ing high-risk patients with advanced rectal cancer is crucial in
providing neoadjuvant treatment only to those who would
benefit mostly from irradiation.
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